Chronic lymphocytic leukaemia (CLL) is one of the most common types of blood cancer and is notable for its varied clinical course and mixed response to therapy.
In order to investigate the biological basis of these variations and discover or validate new drug targets and biomarkers, researchers need access to a large number of high-quality samples. Samples should be obtained from well-defined, uniformly treated patient cohorts, with linkage to relevant baseline and longitudinal clinical data
The UK CLL Biobank fulfils this need by giving researchers access to a single biorepository of CLL samples linked to multiple clinical trials. It has a proven track record of success in driving and facilitating collaborative research.